COX-2 induces immune escape and promotes cancer growth, suggesting the possible benefits of the COX-2 inhibitor celecoxib combined with immunotherapy.183 Over the past several years, a number of clinical trials on neoadjuvant immune checkpoint inhibitor (ICI) have been carried out in MMR-deficient (dMMR) and MMR-proficient (pMMR) colon cancer (NCT03026140). This evidence concerns the gene PTGS2 and malignant colon neoplasm.